Role of Hematological Markers in Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab

被引：0

作者：

Hagiwara, Kohei ^{[1
]}

Matsuki, Takashi ^{[1
,2
]}

Okada, Takuro ^{[3
,4
]}

Fushimi, Chihiro ^{[5
,6
]}

Kondo, Takahito ^{[3
,4
]}

Takahashi, Hideaki ^{[7
]}

Okamoto, Isaku ^{[3
]}

Tokashiki, Kunihiko ^{[3
]}

Hanyu, Kenji ^{[3
]}

Kishida, Takuma ^{[3
]}

Ito, Tatsuya ^{[3
]}

Yamashita, Gai ^{[3
]}

Tsukahara, Kiyoaki ^{[3
]}

Masubuchi, Tatsuo

Tada, Yuichiro

Momiyama, Kaho ^{[1
]}

Yaguchi, Ryohei ^{[2
,7
]}

Oridate, Nobuhiko ^{[7
]}

Omura, Go ^{[6
]}

Yamashita, Taku ^{[1
]}

机构：

[1] Kitasato Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Sagamihara, Japan

[2] Kanagawa Canc Ctr, Dept Head & Neck Surg, 2-3-2 Nakao,Asahi Ku, Yokohama, Kanagawa 2418515, Japan

[3] Tokyo Med Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan

[4] Tokyo Med Univ, Hachioji Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan

[5] Int Univ Hlth & Welf, Mita Hosp, Dept Head & Neck Oncol & Surg, Tokyo, Japan

[6] Natl Canc Ctr, Dept Head & Neck Oncol, Tokyo, Japan

[7] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Japan

来源：

ANTICANCER RESEARCH | 2024年 / 44卷 / 09期

关键词：

Head and neck cancer; pembrolizumab; immune checkpoint inhibitors; hematological marker; real world data; CALLY index; INFLAMMATORY RESPONSE SYNDROME; PROGNOSTIC VALUE; ADVERSE EVENTS; CALLY INDEX; CRP; ASSOCIATION; SURVIVAL; EFFICACY; RATIO;

D O I：

10.21873/anticanres.17235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The predictive role of hematological markers in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with pembrolizumab remains unclear. Patients and Methods: We conducted a multicenter retrospective cohort study to investigate the predictive impact of the pre-treatment hematological markers neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), CRP-albumin-lymphocyte (CALLY) index, and the modified Glasgow prognostic score (mGPS) on overall survival (OS) and progression-free survival (PFS) in patients with R/M SCCHN treated with pembrolizumab. From December 2019 to February 2022, 119 and 28 patients were treated with pembrolizumab alone and pembrolizumab plus chemotherapy, respectively. The optimal cut-off point of dichotomized hematological markers was calculated using the area under the receiver operating characteristic curve. Hazard ratios (HRs) and 95% confidence intervals (95%CIs) were estimated using Cox proportional hazard models with adjustment for potential confounders. Results: In the pembrolizumab monotherapy group, patients with higher NLR, PLR, and mGPS and a lower CALLY index showed significantly shorter OS after adjustment for potential confounders. In addition, all hematological markers examined in this study tended to be associated with clinical response, such as overall response rate or disease control rate (DCR); in particular, a lower CALLY index and higher mGPS were significantly associated with poor DCR. In the pembrolizumab with chemotherapy group, these hematological markers had a similar association with OS but not with clinical response. Conclusion: Pre-treatment NLR, PLR, CALLY index, and mGPS might be predictive markers of survival in patients with R/M SCCHN treated with pembrolizumab.

引用

页码：4057 / 4072

页数：16

共 46 条

[1]

Aoyama Jun, 2021, Cancer Diagn Progn, V1, P353, DOI 10.21873/cdp.10047

[2] Systemic inflammatory response syndrome (SIRS) Where did it come from and is it still relevant today? [J].

Balk, Robert A. .

VIRULENCE, 2014, 5 (01) :20-26

[3] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[4] Innate Immune Responses to Danger Signals in Systemic Inflammatory Response Syndrome and Sepsis [J].

Castellheim, A. ;

Brekke, O. -L. ;

Espevik, T. ;

Harboe, M. ;

Mollnes, T. E. .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2009, 69 (06) :479-491

[5] Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment [J].

Da, Liangshan ;

Qu, Ziting ;

Zhang, Congjun ;

Shen, Yuanyuan ;

Huang, Wei ;

Zhang, Yiyin ;

Gu, Kangsheng .

FRONTIERS IN ONCOLOGY, 2023, 13

[6] Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab [J].

Diem, Stefan ;

Schmid, Sabine ;

Krapf, Mirjam ;

Flatz, Lukas ;

Born, Diana ;

Jochum, Wolfram ;

Templeton, Arnoud J. ;

Fruh, Martin .

LUNG CANCER, 2017, 111 :176-181

[7] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[8] Impact of C-reactive protein-albumin-lymphocyte (CALLY) index on prognosis after hepatectomy for colorectal liver metastasis [J].

Furukawa, Kenei ;

Tsunematsu, Masashi ;

Tanji, Yoshiaki ;

Ishizaki, Shunta ;

Akaoka, Munetoshi ;

Haruki, Koichiro ;

Uwagawa, Tadashi ;

Onda, Shinji ;

Matsumoto, Michinori ;

Ikegami, Toni .

SURGICAL ONCOLOGY-OXFORD, 2023, 47

[9] Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment [J].

Hanahan, Douglas ;

Coussens, Lisa M. .

CANCER CELL, 2012, 21 (03) :309-322

[10] Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma [J].

Hori, Ryusuke ;

Shinohara, Shogo ;

Kojima, Tsuyoshi ;

Kagoshima, Hiroki ;

Kitamura, Morimasa ;

Tateya, Ichiro ;

Tamaki, Hisanobu ;

Kumabe, Yohei ;

Asato, Ryo ;

Harada, Hiroyuki ;

Kitani, Yoshiharu ;

Tsujimura, Takashi ;

Honda, Keigo ;

Ichimaru, Kazuyuki ;

Omori, Koichi .

CANCERS, 2019, 11 (09)

← 1 2 3 4 5 →